Download PDF
Gastroenterologie up2date 2016; 12(03): 249-261
DOI: 10.1055/s-0042-114591
Darm/Anorektum
© Georg Thieme Verlag KG Stuttgart · New York

Interventionelle Verfahren bei metastasiertem kolorektalem Karzinom

Jazan Omari
,
Max Seidensticker
,
Jens Ricke
Further Information

Publication History

Publication Date:
19 September 2016 (online)

Also available at
    Permissions and Reprints All articles of this category
Kernaussagen

Stellenwert

  • Lokale und lokoregionäre Verfahren zur additiven Therapie des metastasierten kolorektalen Karzinoms konnten sich in den letzten Dekaden zunehmend durch überzeugende Daten etablieren und finden vermehrt Akzeptanz in den einschlägigen Guidelines, so auch in den kürzlich neu aufgelegten ESMO-Guidelines. Dies gilt insbesondere für die oligometastasierte Situation.

  • Die Wahl des ablativen Verfahrens obliegt laut ESMO-Guidelines dem multidiziplinären Team vor Ort.

Verfahren

  • Als Verfahren mit einer Chance auf eine R0-Ablation gelten neben der Resektion insbesondere die thermobasierten Verfahren. Gerade bei Tumoren unter 3 cm scheint hier kein Nachteil gegenüber der Resektion zu bestehen.

  • Das lokal-ablative Therapiespektrum wird durch die CT-gesteuerte Hochdosis-Brachytherapie und die stereotaktische Bestrahlung komplettiert, wobei diese Verfahren insbesondere bei ungünstigen Bedingungen für thermobasierte Verfahren (nicht resektable Tumoren > 3 cm und Nähe zu hitzesensiblen Strukturen) zu erwägen sind.

  • Als additiv lokoregionäres Therapieverfahren weist die 90Y-Radioembolisation die solideste Datenlage auf mit resultierender Empfehlung in den ESMO-Guidelines in der Salvage-Situation. Bezüglich der Anwendungsempfehlung der 90Y-Radioembolisation in früheren Stadien (primär First-Line-Therapie) sind Überlebensdaten großer prospektiv randomisierter Studien abzuwarten.

 

  • Literatur

  • 1 Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422
    CrossrefPubMedGoogle Scholar
  • 2 Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19: 1206-1213
    CrossrefPubMedGoogle Scholar
  • 3 Ricke J, Mohnike K, Pech M et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479-485
    CrossrefPubMedGoogle Scholar
  • 4 Siperstein AE, Berber E, Ballem N et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246: 559-565; discussion 565-557
    CrossrefPubMedGoogle Scholar
  • 5 Solbiati L, Ahmed M, Cova L et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012; 265: 958-968
    CrossrefPubMedGoogle Scholar
  • 6 Jakobs TF, Paprottka KJ, Raessler F et al. Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. Eur Radiol 2016; [Epub ahead of print]
    PubMedGoogle Scholar
  • 7 van Hazel GA, Heinemann V, Sharma NK et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 2016; 34: 1723-1731
    CrossrefPubMedGoogle Scholar
  • 8 Van Tilborg AA, Meijerink MR, Sietses C et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol 2011; 84: 556-565
    CrossrefPubMedGoogle Scholar
  • 9 Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23: 1358-1364
    CrossrefPubMedGoogle Scholar
  • 10 Ruers T, Punt C, Van Coevorden F et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23: 2619-2626
    CrossrefPubMedGoogle Scholar
  • 11 Ruers T, Punt C, Van Coevorden F et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 2015; 33 (Suppl. 15) Abstr 3501
    PubMedGoogle Scholar
  • 12 Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17: 1225-1239
    CrossrefPubMedGoogle Scholar
  • 13 Khattak MA, Martin HL, Beeke C et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer 2012; 11: 247-254
    CrossrefPubMedGoogle Scholar
  • 14 Price TJ, Townsend AR, Beeke C et al. “Watchful waiting” for metastatic colorectal cancer, antediluvian or an option to be considered again?. Asia Pac J Clin Oncol 2012; 8: 10-13
    PubMedGoogle Scholar
  • 15 Weiser MR, Jarnagin WR, Saltz LB. Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach?. Oncology (Williston Park) 2013; 27: 1074-1078
    PubMedGoogle Scholar
  • 16 Welsh FK, Tekkis PP, O’Rourke T et al. Quantification of risk of a positive (R1) resection margin following hepatic resection for metastatic colorectal cancer: an aid to clinical decision-making. Surg Oncol 2008; 17: 3-13
    CrossrefPubMedGoogle Scholar
  • 17 Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol 2008; 15: 2757-2764
    CrossrefPubMedGoogle Scholar
  • 18 Tanis E, Nordlinger B, Mauer M et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014; 50: 912-919
    CrossrefPubMedGoogle Scholar
  • 19 Collettini F, Lutter A, Schnapauff D et al. Unresectable colorectal liver metastases: percutaneous ablation using CT-guided high-dose-rate brachytherapy (CT-HDBRT). Rofo 2014; 186: 606-612
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Ricke J, Wust P, Wieners G et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 2004; 15: 1279-1286
    CrossrefPubMedGoogle Scholar
  • 21 Collettini F, Singh A, Schnapauff D et al. Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum. Eur J Radiol 2013; 82: e509-514
    CrossrefPubMedGoogle Scholar
  • 22 Wieners G, Pech M, Rudzinska M et al. CT-guided interstitial brachytherapy in the local treatment of extrahepatic, extrapulmonary secondary malignancies. Eur Radiol 2006; 16: 2586-2593
    CrossrefPubMedGoogle Scholar
  • 23 Peters N, Wieners G, Pech M et al. CT-guided interstitial brachytherapy of primary and secondary lung malignancies: results of a prospective phase II trial. Strahlenther Onkol 2008; 184: 296-301
    CrossrefPubMedGoogle Scholar
  • 24 Ricke J, Wust P, Wieners G et al. CT-guided interstitial single-fraction brachytherapy of lung tumors: phase I results of a novel technique. Chest 2005; 127: 2237-2242
    CrossrefPubMedGoogle Scholar
  • 25 Bester L, Meteling B, Pocock N et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol 2012; 23: 96-105
    CrossrefPubMedGoogle Scholar
  • 26 Seidensticker R, Denecke T, Kraus P et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 2012; 35: 1066-1073
    CrossrefPubMedGoogle Scholar
  • 27 Hendlisz A, Van den Eynde M, Peeters M et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694
    CrossrefPubMedGoogle Scholar
  • 28 Damm R, Seidensticker R, Ulrich G et al. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer 2016; 16: 509
    CrossrefPubMedGoogle Scholar
  • 29 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
    CrossrefPubMedGoogle Scholar
  • 30 Fiorentini G, Aliberti C, Tilli M et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395
    PubMedGoogle Scholar
  • 31 Bhutiani N, Akinwande O, Martin RC et al. Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. World J Surg 2016; 40: 1178-1190
    CrossrefPubMedGoogle Scholar